Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bryostatin 1

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Synaptogenix Gets FDA IND Authorization For Bryostatin-1 In Multiple Sclerosis
    Synaptogenix Gets FDA IND Authorization For Bryostatin-1 In Multiple Sclerosis

    26 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-announces-fda-authorization-of-ind-application-for-clinical-trial-for-bryostatin-1-in-multiple-sclerosis-302182860.html

    PR NEWSWIRE
    26 Jun 2024
    Share Share
    Synaptogenix & Cleveland to Submit IND Application for Trial of Bryostatin-1
    Synaptogenix & Cleveland to Submit IND Application for Trial of Bryostatin-1

    19 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-and-cleveland-clinic-to-submit-investigational-new-drug-ind-application-to-fda-for-clinical-trial-of-bryostatin-1-in-multiple-sclerosis-301880709.html

    PR NEWSWIRE
    19 Jul 2023
    Share Share
    Extended Therapeutic Potential of Synaptogenix's Bryostatin for AD
    Extended Therapeutic Potential of Synaptogenix's Bryostatin for AD

    05 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/new-peer-reviewed-article-demonstrates-extended-therapeutic-potential-of-synaptogenixs-bryostatin-for-alzheimers-disease-301517850.html

    PRNEWSWIRE
    05 Apr 2022
    Share Share
    Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1
    Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1

    23 Feb 2022

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/synaptogenix-moves-forward-with-clinical-development-plans-for-bryostatin-1-1646391047.pdf

    PRESS RELEASE
    23 Feb 2022
    Share Share
    BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1
    BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

    12 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201013005116/en

    BUSINESSWIRE
    12 Oct 2020
    Share Share
    BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI
    BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI

    12 Jun 2020

    // PRESS RELEASE

    https://www.amriglobal.com/blog/news-and-events/news/bryologyx-announces-agreements-with-neurotrope-to-acquire-bryostatin-1-immuno-oncology-data-package-supply-synthetic-bryostatin-1-synthesized-by-amri/

    PRESS RELEASE
    12 Jun 2020
    Share Share